View in EDS HTML Full Text PDF Full Text

A phase II trial of hepatic ablation of metastases to modulate and enhance immunotherapy response in non-small cell lung cancer (HAMMER-NSCLC).

Saved in:
Bibliographic Details
Title: A phase II trial of hepatic ablation of metastases to modulate and enhance immunotherapy response in non-small cell lung cancer (HAMMER-NSCLC).
Authors: McMillan, Matthew T.1 (AUTHOR), Reyngold, Marsha1 (AUTHOR), Crane, Christopher H.1 (AUTHOR), O'Brien, Diana A. Roth1 (AUTHOR), Williams, Vonetta M.1 (AUTHOR), Zinovoy, Melissa1 (AUTHOR), Cuaron, John J.1 (AUTHOR), Gönen, Mithat2 (AUTHOR), Kaiser, Adeel3 (AUTHOR), Sopka, Dennis M.4 (AUTHOR), Gomez, Daniel R.1 (AUTHOR), Schoenfeld, Adam J.5 (AUTHOR), Bott, Matthew6 (AUTHOR), Romesser, Paul B.1 (AUTHOR) romessep@mskcc.org
Source: BMC Cancer. 9/2/2025, Vol. 25 Issue 1, p1-7. 7p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:14712407
DOI:10.1186/s12885-025-14779-5